Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs.

Wells AF, Parrino J, Mangan EK, Paccaly A, Lin Y, Xu C, Fan C, Graham NMH, van Hoogstraten H, Torri A.

Rheumatol Ther. 2019 May 14. doi: 10.1007/s40744-019-0157-3. [Epub ahead of print]

2.

Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.

Choy E, Freemantle N, Proudfoot C, Chen CI, Pollissard L, Kuznik A, Van Hoogstraten H, Mangan E, Carita P, Huynh TM.

RMD Open. 2019 Feb 18;5(1):e000798. doi: 10.1136/rmdopen-2018-000798. eCollection 2019.

3.

Effects of Sarilumab on Patient-Reported Impact of Rheumatoid Arthritis Using the Rheumatoid Arthritis Impact of Disease Scale.

Gossec L, Strand V, Proudfoot C, Chen CI, Guillonneau S, Kimura T, van Hoogstraten H, Mangan E, Reaney M.

J Rheumatol. 2019 Mar 15. pii: jrheum.180904. doi: 10.3899/jrheum.180904. [Epub ahead of print]

4.

Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs.

Choy E, Freemantle N, Proudfoot C, Chen CI, Pollissard L, Kuznik A, van Hoogstraten H, Mangan E, Carita P, Huynh TM.

Adv Ther. 2019 Apr;36(4):817-827. doi: 10.1007/s12325-019-00912-x. Epub 2019 Mar 12.

PMID:
30864105
5.

Mobile device use when caring for children 0-5 years: A naturalistic playground study.

Mangan E, Leavy JE, Jancey J.

Health Promot J Austr. 2018 Dec;29(3):337-343. doi: 10.1002/hpja.38. Epub 2018 Mar 5.

PMID:
30511482
6.

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.

Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR.

Arthritis Res Ther. 2018 Jun 19;20(1):129. doi: 10.1186/s13075-018-1614-z.

7.

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.

Genovese MC, van Adelsberg J, Fan C, Graham NMH, van Hoogstraten H, Parrino J, Mangan EK, Spindler A, Huizinga TWJ, van der Heijde D; EXTEND study investigators.

Rheumatology (Oxford). 2018 Aug 1;57(8):1423-1431. doi: 10.1093/rheumatology/key121.

8.

Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?

Goldman HB, Oelke M, Kaplan SA, Kitta T, Russell D, Carlsson M, Arumi D, Mangan E, Ntanios F.

Int Urogynecol J. 2019 Feb;30(2):239-244. doi: 10.1007/s00192-018-3640-4. Epub 2018 Mar 29.

PMID:
29600400
9.

Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders.

Khusid JA, Weiss JP, Carlsson MO, Mangan EK.

J Urol. 2017 Nov;198(5):1119-1123. doi: 10.1016/j.juro.2017.04.098. Epub 2017 May 4.

PMID:
28479240
10.

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.

Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y, Pacheco-Tena C, Fleischmann R.

RMD Open. 2017 Mar 7;3(1):e000416. doi: 10.1136/rmdopen-2016-000416. eCollection 2017.

11.

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.

Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB.

Ann Rheum Dis. 2017 May;76(5):840-847. doi: 10.1136/annrheumdis-2016-210310. Epub 2016 Nov 17.

12.

Development of a predictive model for urgency urinary incontinence.

Darekar A, Carlsson M, Quinn S, Ntanios F, Mangan E, Arumi D, Scholfield D.

Contemp Clin Trials. 2016 Nov;51:44-49. doi: 10.1016/j.cct.2016.09.005. Epub 2016 Sep 27.

PMID:
27687744
13.

Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.

Chapple C, Schneider T, Haab F, Sun F, Whelan L, Scholfield D, Dragon E, Mangan E.

BJU Int. 2014 Sep;114(3):418-26. doi: 10.1111/bju.12678. Epub 2014 Jul 1.

14.

The unique cytoplasmic domain of human FcγRIIIA regulates receptor-mediated function.

Li X, Baskin JG, Mangan EK, Su K, Gibson AW, Ji C, Edberg JC, Kimberly RP.

J Immunol. 2012 Nov 1;189(9):4284-94. doi: 10.4049/jimmunol.1200704. Epub 2012 Sep 28.

15.

Neural control exploits changing mechanical advantage and context dependence to generate different feeding responses in Aplysia.

Sutton GP, Mangan EV, Neustadter DM, Beer RD, Crago PE, Chiel HJ.

Biol Cybern. 2004 Nov;91(5):333-45. Epub 2004 Oct 27.

PMID:
15517341
16.

Radula-centric and odontophore-centric kinematic models of swallowing in Aplysia californica.

Drushel RF, Sutton GP, Neustadter DM, Mangan EV, Adams BW, Crago PE, Chiel HJ.

J Exp Biol. 2002 Jul;205(Pt 14):2029-51.

17.

C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific.

Stein MP, Edberg JC, Kimberly RP, Mangan EK, Bharadwaj D, Mold C, Du Clos TW.

J Clin Invest. 2000 Feb;105(3):369-76.

18.

FlbT couples flagellum assembly to gene expression in Caulobacter crescentus.

Mangan EK, Malakooti J, Caballero A, Anderson P, Ely B, Gober JW.

J Bacteriol. 1999 Oct;181(19):6160-70.

19.
21.

Supplemental Content

Loading ...
Support Center